Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward
Immunotherapeutic agents may be an attractive option to further improve outcomes and to reduce treatment-related toxicity for pediatric AML. While improvements in outcome have been observed with immunotherapy in many cancer types, immunotherapy development and implementation into patient care for bo...
Main Authors: | Joost B. Koedijk, Inge van der Werf, Friso G. Calkoen, Stefan Nierkens, Gertjan J. L. Kaspers, Christian Michel Zwaan, Olaf Heidenreich |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/17/4364 |
Similar Items
-
Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy
by: Els Lebegge, et al.
Published: (2020-07-01) -
Redirecting the Immune Microenvironment in Acute Myeloid Leukemia
by: Stephanie Sendker, et al.
Published: (2021-03-01) -
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
by: Andrew M. K. Law, et al.
Published: (2020-02-01) -
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
by: Hui Qiu, et al.
Published: (2021-09-01) -
Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune “Defects” in the Tumor Microenvironment
by: Sireesha Upadhrasta, et al.
Published: (2019-09-01)